Clinical trials: Psoriasis Patients
Over 70-year-old Patients with Psoriasis
Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis
Currently, the main systemic drug therapies in China include methotrexate (MTX), cyclosporine A, retinoids, and biologics. In recent years, monoclonal antibody biologics targeting cellular inflammatory factors have been used in…
- Trial name
- NCT06811558
- Testing
- Ixekizumab, Secukizumab
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Psoriasis
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis
This study is a phase I, randomised, double blind (sponsor unblinded), placebo-controlled, single ascending dose study GSK2831781 administered by IV.
- Trial name
- NCT02195349
- Testing
- GSK2831781
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rhumatoid Arthisis, Spondyloarthritis (SA)
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including psoriatic arthritis (PsA), are chronic painful diseases that impair quality of life.
- Conditions
- Rhumatoid Arthisis, Spondyloarthritis (SA), Psoriatic Arthritis (PsA)
- Trial name
- RHUMATOSMART (NCT07460739)
- Testing
- SFR application
- Where
- France
- Volunteers
- 144 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psoriatic Arthritis
Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients
1. Evaluate serum levels of (MCP-1) in PsA with or without cardiovascular affaction . 2. Detect subclinical cardiovascular affaction in patients with PsA for early diagnosis and management .
- Trial name
- NCT05637905
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Assiut University
Healthy Volunteers, Psoriasis
A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis
To assess safety and tolerability of multiple oral doses of BAY1834845 in healthy male subjects (Part 1) and in patients with psoriasis (Part 2).
- Trial name
- NCT03493269
- Testing
- BAY1834845, Midazolam
- Where
- 2 sites in Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Bayer
Psoriasis
A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris
The purpose of the study is to research how much ixekizumab enters the bloodstream and how long the body takes to get rid of the drug and the safety of ixekizumab and any side effects that might be associated with it.
- Trial name
- NCT03073213
- Testing
- Ixekizumab
- Where
- 3 sites in China
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P55 with Cosentyx in patients with moderate to severe plaque psoriasis
- Trial name
- NCT06630559
- Testing
- CT-P55, EU-approved Cosentyx
- Where
- Poland
- Volunteers
- 153 people
- Sponsor
- Celltrion
PsA Patients Fulfilling CASPAR Criteria in Remission
Disparity Between Ultrasound- and Clinical Findings in Psoriatic Arthritis in Remission
Comparison of the proportion of Psoriatic arthritis patients in ultrasound remission (i.e. no power Doppler synovitis, tenosynovitis, dactylitis, enthesitis, PD=0) depending on whether patient and physician's global assessment of…
- Trial name
- PARURE (NCT03396679)
- Testing
- Ultrasound examination
- Where
- France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Montpellier
Psoriasis Vulgaris
Improvement of Psoriasis Patients' Adherence to Topical Drugs
Psoriasis affects 2-4% of the Western adult population and is a socio-economic burden for patients and society. Topical drugs are recommended as first-line treatment for mild-to-moderate psoriasis, but low adherence is a barrier…
- Trial name
- NCT04220554
- Testing
- Improved support by health-care professionals
- Where
- Denmark
- Volunteers
- 103 people
- Sponsor
- Odense University Hospital
Plaque Psoriasis
Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients
M5181 - a novel vitamin D3 analogue - is currently under development for the treatment of plaque psoriasis and is being developed as a topical ointment formulation (M518101) Clinical and non-clinical studies indicate that M5181…
- Trial name
- NCT01989429
- Testing
- M518101
- Where
- 6 sites in Austria, Bulgaria and 4 more
- Volunteers
- 788 people
- Sponsor
- Maruho Europe Limited
Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity Between Patients with Moderate to Severe Chronic Plaque Psoriasis Receiving Humira® and Patients with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT04453137
- Testing
- Adalimumab originator, Adalimumab biosimilar
- Where
- 25 sites in Georgia, Iceland and 3 more
- Volunteers
- 567 people
- Sponsor
- Alvotech Swiss AG
Arthritis, Rheumatoid, Psoriatic Arthritis
Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Diseases
Introduction: The medical treatment of inflammatory rheumatic diseases has improved dramatically during the last decades primarily due to the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs).
- Conditions
- Arthritis, Rheumatoid, Psoriatic Arthritis, Axial Spondyloarthritis, Connective Tissue Diseases
- Trial name
- NCT03214263
- Where
- 11 sites in Denmark
- Volunteers
- 20,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Psoriasis, Atopic Dermatitis/ Eczema
Haut-Tief Patient Education on Psoriasis and Eczema
'Haut-Tief' (Skin Deep) is an educational, stress reducing program for patients with psoriasis or atopic dermatitis. A range of support activities will be offered in order to learn effective self-management strategies and…
- Trial name
- NCT02205593
- Testing
- Control
- Where
- Switzerland
- Volunteers
- 80 people
- Sponsor
- University of Zurich
COVID-19, SARS-CoV Infection
Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases
The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples.
- Conditions
- COVID-19, SARS-CoV Infection, Rheumatoid Arthritis, Spondyloarthritis
- Trial name
- COVID-RIC1 (NCT04655612)
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- University Hospital, Montpellier
Rheumatoid Arthritis, Psoriatic Arthritis
Prospective Analysis of Blood Flow Restriction Training in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Compared to Conventional Strength Training
This single-centre, randomized prospective interventional study assesses the effect of blood flow restriction training in patients with rheumatoid arthritis compared with conventional resistance training.
- Trial name
- BFR-RA/PSA (NCT07772687)
- Testing
- Blood Flow Restriction Training (BFRT), Conventional Strength Training
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- University of Bonn
Psoriasis
Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis
Psoriasis, the most prevalent autoimmune disease in the U.S., manifests with plaque type psoriasis vulgaris with lesions localized to the scalp, postauricular region, face, diaper area, elbows, and knees.
- Trial name
- NCT03848806
- Testing
- HAT1, Calcipotriol
- Volunteers
- 174 people
- Sponsor
- Haus Bioceuticals
Arthritis, Psoriatic
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
This study is undertaken to compare the efficacy and onset of action of infliximab plus methotrexate (IFX + MTX) versus methotrexate alone (MTX) in methotrexate naïve active psoriatic arthritis patients.
- Trial name
- NCT00367237
- Testing
- Infliximab + methotrexate (IFX + MTX), Methotrexate (MTX)
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)
Subjects with moderate-to-severe chronic psoriasis not responding to standard or biologic therapy will be eligible to enroll in this study.
- Trial name
- ESAQUALITY (NCT00687401)
- Testing
- Infliximab
- Volunteers
- 215 people
- Sponsor
- Merck Sharp & Dohme LLC
Generalized Pustular Psoriasis
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.
- Trial name
- NCT06886009
- Testing
- Spevigo®
- Where
- 4 sites in South Korea
- Sponsor
- Boehringer Ingelheim
Plaque Psoriasis
BTT1023 in Psoriasis
Patients with plaque psoriasis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of BTT-1023 will be assessed.
- Trial name
- NCT00871598
- Testing
- BTT1023
- Where
- 5 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Biotie Therapies Corp.